Almeda Ventures
Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA) that invests globally in HealthTech — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with capital, regulatory, clinical, and strategic support.
- Company typePublic
- Founded2020
- HeadquartersTel Aviv, Israel
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Almeda Ventures does
Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA on the Tel Aviv Stock Exchange) and the first HealthTech-focused public partnership of its kind in Israel. Founded in 2020 and headquartered in Tel Aviv, the firm invests globally across three verticals — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with proven clinical concepts and validated business models. Its portfolio of approximately ten disclosed companies spans surgical AR (Augmedics xvision), minimally invasive robotic instruments (FlexDex), soft tissue repair (Nurami Medical), neuromuscular stimulation (Virility), cancer care navigation (Belong), metabolic monitoring (Lumen), AI-driven elder care (Sensi.AI), radiotherapy protection (BioProtect), peripheral arterial disease treatment (NovaPulse), and healthcare financial technology (TailorMed). The firm does not develop proprietary technology products; instead, its offering is investment capital combined with strategic, regulatory, clinical, IP, and reimbursement support delivered through a lean core team and a specialized advisory bench.
Revenue mechanics for Almeda are those of an investment vehicle rather than an operating business: returns accrue to unit holders through capital appreciation and exit events (acquisitions, IPOs) across the portfolio, supplemented by participation in follow-on rounds. The core team — Founding Partners Dr. Irit Yaniv (also Chairperson) and Amir Blatt, CEO Manor Zemer, CFO Efrat Hess, and Director Tzahi Sultan — is supported by named advisors covering clinical (Dr. Ori Ben-Yehuda), reimbursement (Dr. Joel Brill), IP (Dr. Michal Fisher), and regulatory (Dr. Susan Alpert, ex-FDA and Medtronic) domains. Distribution and deal sourcing rely on direct networks, industry events (Biomed Israel, ICI), LinkedIn, and the corporate website. Co-investment relationships with Accelmed and Olive Tree Ventures alumni connections provide a deal-flow pipeline, while the TASE listing gives the entity differentiated access to public capital relative to conventional closed-end Israeli VC funds.
Almeda Ventures firmographics
Firmographics- Name
- Almeda Ventures
- Legal name
- Almeda Ventures
- Website
- https://almedaventures.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Almeda Ventures is a publicly traded Israeli R&D partnership (AMDA.TA) that invests globally in HealthTech — medical devices, digital health, and bio-convergence — backing early- and growth-stage companies with capital, regulatory, clinical, and strategic support.
- Ownership category
- akta.pro rank
Almeda Ventures industry classification
Industry- Product category
- Venture Capital / HealthTech Investment
- NAICS
- Portfolio Management and Investment Advice (523940), Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)
- SIC
- Investment Advice (6282), Services-Management Consulting Services (8742)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industries
- Regulatory Strategy & IND/NDA/BLA Submissions Support (HLAIALAH), Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
Keywords
Where Almeda Ventures is headquartered
LocationHeadquarters
- HQ city
- Tel Aviv
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Almeda Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Others
Revenue model
- Investment Returns: Almeda Ventures generates returns through equity investments in HealthTech companies. As a public R&D partnership listed on the Tel Aviv Stock Exchange (AMDA.TA), they benefit from capital appreciation of portfolio companies and potential exit events including acquisitions and IPOs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Almeda Ventures product offering
Product offeringCore offering
Almeda Ventures is the first HealthTech-focused public R&D partnership (TASE: AMDA.TA), investing globally in early- and growth-stage medical device, digital health, and bio-convergence companies. It deploys equity capital and provides strategic guidance, regulatory and reimbursement expertise, and access to a network of investors, strategics, and medical centers to help portfolio companies progress from clinical concept to commercial success and exit.
Product overview
Almeda Ventures is a HealthTech-focused public R&D partnership (traded as AMDA.TA on the Tel Aviv Stock Exchange) that invests globally in medical devices, digital health, and bio-convergence. The company is not itself a product manufacturer; rather it provides investment and support to a portfolio of early- and growth-stage HealthTech companies. The portfolio includes ten distinct portfolio companies spanning surgical augmentation (Augmedics xvision), minimally invasive surgical instruments (FlexDex Surgical), neurological tissue repair (Nurami Medical), urology (Virility Medical), cancer care management (Belong), metabolic health monitoring (Lumen), AI-powered senior care quality (Sensi.AI), radiotherapy protection (BioProtect ProSpace Balloon System), peripheral arterial disease treatment (NovaPulse), and healthcare financial technology (TailorMed).
Differentiator
Problem solved
Functional benefit
Products and services
- Almeda Ventures HealthTech R&D Partnership
Companies that use Almeda Ventures
Customer profileSegments1 record
Ideal customer profiles1 record
Almeda Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Almeda Ventures partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered minor.
- 8400 ProjectminorAlmeda's Dr. Irit Yaniv is an active participant in the 8400 project (cohort 2), an Israeli healthcare innovation initiative.
- Life Science Women ForumminorCo-founded by Almeda's Dr. Irit Yaniv, a forum focused on women empowerment in the life sciences sector.
- We@HealthcareminorCo-founded by Almeda's Dr. Irit Yaniv, a women empowerment initiative in healthcare.
- Meuhedet Health ServicesminorAlmeda's CEO Manor Zemer serves as a council member of Meuhedet Health Services, contributing expertise in investment strategy and governance.
Scale indicators3 records
Recent moves6 records
Expansion highlights5 records
Almeda Ventures competitors and assessment
Company assessmentDirect peers
- Accelmed: Accelmed is a global HealthTech-focused PE/VC group investing in commercial-stage and growth-stage medical companies. It is Almeda's closest direct peer — co-founders Dr. Irit Yaniv and Amir Blatt were Accelmed partners, and the firms continue to co-invest — making Accelmed the most structurally and thematically comparable entity.
- Olive Tree Ventures (OTV): Israel-based $170M digital health VC fund. Almeda CEO Manor Zemer was previously a Partner at OTV, and the funds share a focus on Israeli HealthTech. OTV is a direct peer in stage, geography, and vertical.
- Qumra Capital: Israeli growth-stage venture fund investing in technology and healthcare. Qumra led Sensi.AI's $45M Series C with Almeda participating, making it a directly comparable co-investor and peer in the Israeli HealthTech growth space.
- Pitango Venture Capital: One of Israel's largest and most active venture capital firms with a dedicated HealthTech practice. Pitango invests across stages in Israeli medical device, digital health, and biotech companies — directly overlapping Almeda's investment focus and geography.
- OurCrowd: Israel-based global venture investing platform with active HealthTech and digital health portfolios. OurCrowd is a direct comparable in Israeli HealthTech venture deployment, particularly for early to growth-stage deals.
- Windham Capital Partners: Growth-stage healthcare investor that led TailorMed's $40M round with Almeda participating. Windham is a directly comparable growth-equity peer in HealthTech with overlapping portfolio themes.
- Trendlines Group: Israeli-listed (SGX) medical and agrifood technology incubator and investor. Trendlines is a direct peer in Israeli medtech early-stage investing and is itself publicly traded like Almeda, making it a structural as well as thematic comparable.
Broad incumbents
- Insight Partners: Large global software and HealthTech investor. Insight Partners co-invested in Sensi.AI alongside Almeda and is a broader incumbent in the digital health and growth equity space, competing for later-stage Israeli deals.
- General Catalyst: Global venture capital firm with a large Health Assurance / healthcare practice. While broader than Almeda, General Catalyst competes for the same digital health and bio-convergence deals and is a leading global HealthTech incumbent.
Regional players
- aMoon Fund: Israel-based global HealthTech and life sciences investor founded by Marius Nacht. aMoon is a regional HealthTech peer with similar investment focus, Israeli roots, and global deployment — overlapping with Almeda in portfolio construction.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Almeda Ventures social profiles
Digital presenceAlmeda Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Almeda Ventures leadership team
Management profileNumber of profiles
Profiles1 record
Almeda Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Almeda Ventures M&A and investment
M&A and investmentM&A
Investments11 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Almeda Ventures
What does Almeda Ventures do?
Almeda Ventures is the first HealthTech-focused public R&D partnership (TASE: AMDA.TA), investing globally in early- and growth-stage medical device, digital health, and bio-convergence companies. It deploys equity capital and provides strategic guidance, regulatory and reimbursement expertise, and access to a network of investors, strategics, and medical centers to help portfolio companies progress from clinical concept to commercial success and exit.
Is Almeda Ventures a public or private company?
Almeda Ventures is a public company. It is classified as public and is currently operating.
When was Almeda Ventures founded?
Almeda Ventures was founded in 2020. It employs 1 to 10 people.
Where is Almeda Ventures based?
Almeda Ventures is headquartered in Tel Aviv, Israel, in the Middle East region.
How does Almeda Ventures make money?
One revenue line is on record: investment Returns.
Who are Almeda Ventures's main competitors?
Direct peers on record are Accelmed, Olive Tree Ventures (OTV), Qumra Capital, Pitango Venture Capital, OurCrowd, Windham Capital Partners and Trendlines Group. Broad incumbents are Insight Partners and General Catalyst. aMoon Fund is listed as a regional player.
Does Almeda Ventures have an API?
No public API is recorded for Almeda Ventures.
What industry is Almeda Ventures in?
Almeda Ventures's product category is Venture Capital / HealthTech Investment. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of HLAIALAH, Regulatory Strategy & IND/NDA/BLA Submissions Support. Its NAICS code is 523940 and its SIC code is 6282.